

The proposal of the nomination committee: **Marie-Louise Fjällskog** to be elected as a new Board member for a term that ends at the end of the next AGM.



Marie-Louise Fjällskog, M.D., Ph.D. Dr. Fjällskog has over 30 years of experience in clinical oncology, translational research, and drug development. She had joined Faron from Sensei Biotherapeutics (SNSE), a Nasdaq listed immuno-oncology company. As Chief Medical Officer at Sensei, she was responsible for leading clinical and development strategy and operations. She also played a key role in Sensei's successful \$152 million IPO, which closed in February 2021. Previously, she served as Vice President, Clinical Development at Merus (MRUS) and Infinity Pharmaceuticals (INFI) where she led development of multiple small molecule and immuno-oncology clinical programs. She was formerly Global Clinical Program Leader at the Novartis Institute for Biomedical Research where she led global development of oncology treatments targeting CDK4/6, BCL-2, PD-1, CSF-1 and CD73. Dr. Fjällskog holds both a M.D. and Ph.D. from Uppsala University, Sweden where she serves as an Associate Professor of Oncology. Dr. Fjällskog also serves on the Board of Biovica, a Swedish biotech company, and Lytix Biopharma, a clinical stage biotech developing novel cancer immunotherapies.

